INM-901 / InMed Pharma - LARVOL DELTA

2026 Development Priorities for INM-901 include (Investing News Network (INN)) - "Conduct a pre-IND meeting with the U.S. Food and Drug Administration in Q3/2026; Continue to execute on IND-enabling pharmacology and toxicology studies; Continued development and scale up of drug substance and product manufacturing activities to support IND enabling studies and submission; Engage regulatory/clinical experts to map out topline clinical design for first in human clinical trials for the INM-901; Subject to regulatory feedback and completion of IND-enabling activities, the Company targets submission of an IND and initiation of a Phase 1 clinical trial in 2027."

First-in-human • IND • New P1 trial • Alzheimer's Disease

Drug Development. (PubMed, Alzheimers Dement) - "INM-901 treatment reversed several behavioral changes, improved auditory deficits, decreased Aβ-aggregation, and modulated inflammatory and neuritogenesis markers in 5xFAD mice. These findings highlight the potential of INM-901 as a therapeutic candidate for AD and provide a basis for further evaluation in tauopathy and inflammatory neurodegenerative models."

Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Inflammation • Mood Disorders • Psychiatry • NEFL

InMed Pharmaceuticals Demonstrates INM-901 as an Oral Formulation Targeting Alzheimer’s Disease (Newsfile) - "InMed Pharmaceuticals Inc...today confirms INM-901 as an oral formulation that will be utilized in its development programs for Alzheimer's disease. Recent preclinical studies have demonstrated that INM-901, a proprietary small molecule drug candidate, can be administered orally and achieve therapeutic levels in the brain comparable to those obtained through intraperitoneal ('IP') injection, which is a common route of administration for preclinical investigation of neurodegenerative diseases. The data indicates the INM-901 formulation can be administered orally and maintains a similar drug exposure levels as IP delivery over a 24-hour period in the brain."

Preclinical • Alzheimer's Disease • CNS Disorders

InMed Pharmaceuticals Inc.’s INM-901 Demonstrates Unique Pharmacological Effects in Alzheimer’s Disease in Preclinical Proof-of-Concept Studies (Yahoo Finance) - "InMed Pharmaceuticals Inc...announced it has selected a lead Alzheimer's disease drug candidate, named INM-901, following positive results from several proof-of-concept studies in a validated Alzheimer's disease treatment model. InMed will be advancing INM-901, a cannabinoid analog, in its pharmaceutical drug development program....In addition to these encouraging in vitro testing outcomes, INM-901 demonstrated favorable results in an in vivo preclinical Alzheimer's proof-of-concept model. When compared to the placebo treated Alzheimer's disease group in these preclinical studies, INM-901 treatment groups demonstrated a trend towards improvement in: cognitive function and memory; locomotor activity; anxiety-based behavior; sound awareness..."

Preclinical • Alzheimer's Disease • CNS Disorders